Brief: Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol
12/05/2025 13:28
May 12 (Reuters) - Esperion Therapeutics Inc ESPR.O: ESPERION REACHES SETTLEMENT AGREEMENT WITH ANDA FILER NOT TO MARKET GENERIC VERSION OF NEXLETOL® (BEMPEDOIC ACID) PRIOR TO APRIL 19, 2040 ESPERION THERAPEUTICS INC - MICRO LABS AGREES NOT TO MARKET GENERIC NEXLETOL BEFORE 2040 ESPERION THERAPEUTICS INC - SETTLES PATENT LITIGATION WITH MICRO LABS Source text: ID:nGNXbvwz99 Further company coverage: ESPR.O
Recent news on Esperion Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP- Applied Materials, Axsome Therapeutics, Onsemi